Investing.com -- AstraZeneca has changed its pricing strategy for new drug launches in response to U.S. President Donald Trump's "most-favoured-nation" policy, which aims to reduce drug prices for Americans, a senior company executive said on Monday.

David Fredrickson, AstraZeneca's executive vice president for the oncology business, told investors that the company's pricing approach across all launches has evolved in response to the most-favoured-nation policy.

The most-favoured-nation policy seeks lower drug prices for Americans.